Dulcineia Martins de Albuquerque
Overview
Explore the profile of Dulcineia Martins de Albuquerque including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
136
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
da Silva Costa S, Ito M, da Cruz P, de Souza B, Rios V, Bertozzo V, et al.
Exp Biol Med (Maywood)
. 2024 Aug;
249:10070.
PMID: 39114443
HbSC disease, a less severe form of sickle cell disease, affects the retina more frequently and patients have higher rates of proliferative retinopathy that can progress to vision loss. This...
2.
Toreli A, Toni I, de Albuquerque D, Lanaro C, Maues J, Yotsumoto Fertrin K, et al.
Hematol Transfus Cell Ther
. 2024 May;
46 Suppl 5:S197-S200.
PMID: 38719717
Background: Iron overload (IO) is a complex condition in which clinical, behavioral and genetic factors contribute to the phenotype. In multiethnic and non-Caucasian populations, mutations in HFE gene alone cannot...
3.
de Castro J, da Silva Costa S, Camargo A, Ito M, de Souza B, Bertozzo V, et al.
Ann Hematol
. 2024 Feb;
103(4):1167-1179.
PMID: 38386032
Ischemic stroke (IS) is one of the most impairing complications of sickle cell anemia (SCA), responsible for 20% of mortality in patients. Rheological alterations, adhesive properties of sickle reticulocytes, leukocyte...
4.
Bertozzo V, da Silva Costa S, Ito M, da Cruz P, Souza B, Rios V, et al.
Exp Biol Med (Maywood)
. 2023 Apr;
248(8):677-684.
PMID: 37012663
Among sickle cell anemia (SCA) complications, proliferative sickle cell retinopathy (PSCR) is one of the most important, being responsible for visual impairment in 10-20% of affected eyes. The aim of...
5.
Furlaneto Marega L, Sabino J, Pedroni M, Teocchi M, Lanaro C, de Albuquerque D, et al.
Immunol Res
. 2021 Aug;
69(5):445-456.
PMID: 34390446
STAT3 is a cytokine-signaling transcription factor critical for gene regulation. Gain-of-function (GOF) mutations in STAT3 are associated with lymphoproliferation, autoimmune cytopenias, increased susceptibility to infection, early-onset solid-organ autoimmunity, short stature,...
6.
Sesti-Costa R, Borges M, Lanaro C, de Albuquerque D, Saad S, Costa F
Front Immunol
. 2021 Feb;
11:617962.
PMID: 33613546
Sickle cell disease (SCD), one of the most common hemoglobinopathies worldwide, is characterized by a chronic inflammatory component, with systemic release of inflammatory cytokines, due to hemolysis and vaso-occlusive processes....
7.
Vila Cuenca M, Marchi G, Barque A, Esteban-Jurado C, Marchetto A, Giorgetti A, et al.
Int J Mol Sci
. 2020 Apr;
21(7).
PMID: 32235485
Aceruloplasminemia is a rare autosomal recessive genetic disease characterized by mild microcytic anemia, diabetes, retinopathy, liver disease, and progressive neurological symptoms due to iron accumulation in pancreas, retina, liver, and...
8.
Santos B, Jorge S, de Albuquerque D, Gilli S, Sonati M, Yotsumoto Fertrin K, et al.
Blood Cells Mol Dis
. 2019 Aug;
79:102353.
PMID: 31445464
No abstract available.
9.
Borges M, de Albuquerque D, Lanaro C, Costa F, Yotsumoto Fertrin K
Am J Med Genet B Neuropsychiatr Genet
. 2019 Mar;
180(4):266-271.
PMID: 30901137
Aceruloplasminemia is a rare form of brain iron overload of autosomal recessive inheritance that results from mutations in the CP gene, encoding the iron oxidase ceruloplasmin. Homozygous aceruloplasminemia causes progressive...
10.
Ribeiro B, Miranda E, de Albuquerque D, Delamain M, Oliveira-Duarte G, Almeida M, et al.
Clinics (Sao Paulo)
. 2015 Aug;
70(8):550-5.
PMID: 26247667
Objective: To evaluate hematological, cytogenetic and molecular responses as well as the overall, progression-free and event-free survivals of chronic myeloid leukemia patients treated with a third tyrosine kinase inhibitor after...